Top Research Reports for Applied Materials, Mastercard & AbbVie
Applied Materials is riding AI-driven chip demand, but can record margins, new products and China-related risks shape its next phase of growth?
Zacks
More News
J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates may give one stock an edge.
Zacks
Here's How Much $1000 Invested In AbbVie 5 Years Ago Would Be Worth Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 5.03% on an annualized basis producing an average annual return of 16.59%. Currently, AbbVie has a market capitalization of $442.79 billion.read more...
Benzinga
J&J's Innovative Medicine Business in Q2: Here's What to Watch
JNJ's Q2 Innovative Medicine results face scrutiny as Stelara biosimilar pressure offsets growth from key blockbusters and newer therapies ahead of earnings.
Zacks
What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
ABBV surged nearly 11% in a week as acquisitions, new approvals and pipeline expansion strengthen confidence in its long-term growth strategy.
Genmab reports positive Phase 3 EPCORE DLBCL-4 results in relapsed lymphoma; analyst points to label expansion and future growth opportunities.read more...
Benzinga
Merck, AbbVie Hit With Congressional Probe Over China Drug Trials: Report
US lawmakers probe Merck and AbbVie over national security and ethical risks tied to clinical trials conducted in China.read more...
Benzinga
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
Zacks
Nxera Receives $10 Mln Milestone Payment From AbbVie
(RTTNews) - Nxera Pharma Co., Ltd. (SOLTF) on Tuesday said it received a $10 million milestone payment from AbbVie (ABBV) after achieving a fourth R&D milestone under their multi-target drug discovery collaboration focused on neurological diseases...
Nasdaq News: Markets
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma PR...